Last reviewed · How we verify
Iprazid (IPRONIAZID)
Iprazid (generic name: IPRONIAZID) is a Monoamine Oxidase Inhibitors drug. It is currently in Phase 2 development for Depressive disorder.
Iproniazid works by blocking the enzyme that breaks down certain neurotransmitters, allowing their levels to increase in the brain.
Iprazid is a small molecule inhibitor of the enzyme monoamine oxidase. It is classified as a monoamine oxidase inhibitor, a drug class that inhibits the action of monoamine oxidase.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | IPRONIAZID |
|---|---|
| Drug class | Monoamine Oxidase Inhibitors |
| Target | Amine oxidase [flavin-containing] A |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | Phase 2 |
Mechanism of action
Imagine your brain is a city with many roads. Neurotransmitters are like cars that travel along these roads, carrying messages between different parts of the brain. Iproniazid is like a traffic cop that stops the 'breakdown' of these cars, allowing more of them to be available to carry messages, which can help improve mood and reduce symptoms of depression.
Approved indications
- Depressive disorder
Common side effects
Drug interactions
- Alpha/Beta Agonists
- Amphetamines
- Indirectly Acting Sympathomimetic Amines
- Selective Serotonin Reuptake Inhibitors
- Serotonin/Norepinephrine Reuptake Inhibitors
- Tricyclic Antidepressants
- buspirone
- dextromethorphan
- levodopa
- methyldopa
- mirtazapine
- pethidine
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Iprazid CI brief — competitive landscape report
- Iprazid updates RSS · CI watch RSS
Frequently asked questions about Iprazid
What is Iprazid?
How does Iprazid work?
What is Iprazid used for?
What is the generic name of Iprazid?
What drug class is Iprazid in?
What development phase is Iprazid in?
What does Iprazid target?
Related
- Drug class: All Monoamine Oxidase Inhibitors drugs
- Target: All drugs targeting Amine oxidase [flavin-containing] A
- Therapeutic area: All drugs in Neuroscience
- Indication: Drugs for Depressive disorder
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing